Tarsus Pharmaceuticals, Inc.
NASDAQ: TARS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bobak R. Azamian
- Employees
- 323
- Headquarters
- Irvine, United States
- IPO year
- 2020
- Market cap
- $2.9B
- Website
- https://www.tarsusrx.com
Loading TARS…
Loading profile data…Frequently asked questions about TARS
What does Tarsus Pharmaceuticals, Inc. (TARS) do?
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite i...
Where does TARS trade?
Tarsus Pharmaceuticals, Inc. (TARS) trades on the NASDAQ Global Select.
What sector is TARS in?
Tarsus Pharmaceuticals, Inc. (TARS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tarsus Pharmaceuticals, Inc.?
Bobak R. Azamian is the chief executive officer of Tarsus Pharmaceuticals, Inc. (TARS).
Where is Tarsus Pharmaceuticals, Inc. headquartered?
Tarsus Pharmaceuticals, Inc. is headquartered in United States.
Does TARS pay a dividend?
Tarsus Pharmaceuticals, Inc. (TARS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TARS go public?
Tarsus Pharmaceuticals, Inc. (TARS) completed its initial public offering in 2020.